Related Experiment Video
Updated: Dec 30, 2025

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
Published on: August 20, 2019
Association between impaired cutaneous microvascular endothelial function and lectin-like oxidized low-density
Jian Zhao1, Yanda Zhang1, Zhigang Huang1
1Department of Cardiology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Insights
Patients with coronary slow flow (CSF) exhibit impaired cutaneous microvascular endothelial function. This dysfunction is linked to elevated levels of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1).
Area of Science:
- Cardiovascular Medicine
- Microvascular Physiology
- Biomarkers
Background:
- Coronary slow flow (CSF) is increasingly recognized as a systemic microvascular disorder.
- The status of cutaneous microvascular endothelial function in CSF patients remains incompletely understood.
- This study investigates the link between CSF and skin microvascular health.
Purpose of the Study:
- To determine if cutaneous microvascular endothelial function is impaired in patients with coronary slow flow (CSF).
- To examine the correlation between impaired cutaneous microvascular endothelial function and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in CSF patients.
Main Methods:
- 39 CSF patients and 45 controls were assessed using the thrombolysis in myocardial infarction frame count (TFC) for coronary flow.
- Cutaneous blood flow responses to passive limb movement (PORH) were measured using a laser Doppler flowmetry system (LSCI).
- Serum levels of soluble LOX-1 (sLOX-1) were quantified in all participants.
Main Results:
- CSF patients showed significantly reduced PORH-induced vasodilation compared to controls (P < 0.001).
- Serum sLOX-1 levels were significantly higher in CSF patients (P < 0.001) and correlated positively with mean TFC.
- Impaired vasodilation in CSF patients negatively correlated with serum sLOX-1 levels (r = -0.588, P < 0.001).
Conclusions:
- Cutaneous microvascular endothelial function is demonstrably impaired in patients with coronary slow flow (CSF).
- Increased expression of LOX-1 is closely associated with this impaired microvascular function in CSF.
- These findings highlight a potential systemic microvascular component in CSF.
Objective:
Although increasing studies indicate coronary slow flow (CSF) is a systemic microvascular disorder, whether there is impaired cutaneous microvascular endothelial function in CSF patients remains unclear. This study was designed to test the hypothesis that the cutaneous microvascular endothelial function of CSF patients is impaired and correlates with lectin-like oxidized low-density lipoprotein receptor-1(LOX-1).
Methods:
39 patients with CSF and 45 controls with normal coronary flow were enrolled. Velocity of coronary flow was quantitatively identified by thrombolysis in myocardial infarction frame count (TFC) method. LSCI system was used to assess subjects' cutaneous blood flow at rest and during PORH. Serum soluble LOX-1(sLOX-1) level was measured in all study subjects.
Results:
PORH-induced vasodilation was significantly reduced in CSF group in comparison with control group (0.26 ± 0.10 vs 0.35 ± 0.07 APU/mmHg, P < 0.001) and negatively correlated with the mean TFC for three coronary arteries (r = -0.385, P = 0.016). Serum sLOX-1 level in CSF group was significantly increased (582.93 ± 74.89 vs 483.64 ± 51.38 pg/ml, P < 0.001) and positively correlated with mean TFC(r = 0.467, P = 0.003).PORH response amplitudes had a significantly negative relationship with serum sLOX-1 level in CSF patients (r = -0.588, P < 0.001).
Conclusion:
These data suggest that cutaneous microvascular endothelial function is impaired in patients with CSF, which is closely associated with increased LOX-1 expression.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Peripheral Artery Disease I: Introduction
Coronary Artery Disease I: Introduction
Atherosclerosis I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

